



Form PTO-1449 (modified)

Atty. Docket No.
CLFR:234USSerial No.
10/602,303

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
Bharat AggarwalFiling Date:
June 24, 2003Group:
1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
✓	A1	2001/0025034	11/27/01	Arbiser	514	114	1/18/01
	A2	2002/0019382	2/14/02	Snyder <i>et al.</i>	514	210.2	12/4/00
	A3	2002/0035090	3/21/02	Zeldis	514	58	5/14/01
	A4	2004/002499	1/01/04	Aggarwal	514	251	4/24/03
	A5	2005/0049299	3/03/05	Aggarwal	514	456	8/25/04
✓	A6	5,891,924	4/6/99	Aggarwal	514	679	9/26/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
							h

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C1	Brennan <i>et al.</i> , "Inhibition of nuclear factor kappaB by direct modification in whole cells-- mechanism of action of nordihydroguaiaretic acid, curcumin and thiol modifiers," <i>Biochem. Pharmacol.</i> , 55:965-973, 1998.
✓	C2	Cheng <i>et al.</i> , "Phase I chemoprevention clinical trial of curcumin," <i>Proc. Am. Soc. Clin. Oncol.</i> 17:558a, 1998.
✓	C3	Estrov <i>et al.</i> , "Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells," <i>Blood</i> , 94:2844-2853, 1999.
✓	C4	Feinman <i>et al.</i> , "Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2," <i>Blood</i> , 93:3044-3052, 1999.

25527582.1

EXAMINER: *Reeves*

DATE CONSIDERED:

8/1/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
CLFR:234USSerial No.
10/602,303

1 List of Patents and Publications for Applicant's
 MAY 09 2005 INFORMATION DISCLOSURE STATEMENT
 (Use several sheets if necessary)

Applicant
Bharat AggarwalFiling Date:
June 24, 2003Group:
1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
h	C5	Giri and Aggarwal, "Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates," <i>J. Biol. Chem.</i> , 273:14008-14014, 1998.
	C6	Han <i>et al.</i> , "Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53," <i>Clin. Immunol.</i> , 93:152-161, 1999.
	C7	Hour <i>et al.</i> , "Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation," <i>Prostate</i> , 51:211-218, 2002.
	C8	Huang <i>et al.</i> , "Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice," <i>Carcinogenesis</i> , 19:1697-1700, 1998.
	C9	Ichiki <i>et al.</i> , "Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer," <i>Clin. Exp. Metastasis</i> , 18:539-545, 2001.
	C10	Inano <i>et al.</i> , "Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with gamma-rays," <i>Carcinogenesis</i> , 20:1011-1018, 1999.
	C11	Jaffe <i>et al.</i> , "Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma," <i>N. Engl. J. Med.</i> , 291:994-997, 1974.
	C12	Jang <i>et al.</i> , "A curcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria," <i>Planta Med.</i> 67:550-552, 2001.
	C13	Jaruga <i>et al.</i> , "Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes," <i>FEBS Lett.</i> , 433(3):287-293, 1998.
	C14	Jobin <i>et al.</i> , "Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity," <i>J. Immunol.</i> , 163:3474-3483, 1999.
✓	C15	Kawamori <i>et al.</i> , "Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer," <i>Cancer Res.</i> 59:597-601, 1999.

25527582.1

EXAMINER:

n Cook

DATE CONSIDERED:

8/1/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:234US	Serial No. 10/602,303
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Bharat Aggarwal	
		Filing Date: June 24, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
✓	C16	Kumar <i>et al.</i> , "Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation," <i>Biochem. Pharmacol.</i> , 55:775-783, 1998.
	C17	Mehta <i>et al.</i> , "Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines," <i>Anti-Cancer Drugs</i> , 8:470-481, 1997.
	C18	Menon <i>et al.</i> , "Anti-metastatic activity of curcumin and catechin," <i>Cancer Lett.</i> , 141:159-165, 1999.
	C19	Mohan <i>et al.</i> , "Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B," <i>J. Biol. Chem.</i> , 275:10405-10412, 2000.
	C20	Navis <i>et al.</i> , "Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma," <i>Pharmacol. Res.</i> , 39:175-179, 1999.
	C21	Ni <i>et al.</i> , "Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis," <i>Br. J. Haematol.</i> 115:279-286, 2001.
	C22	Pahl <i>et al.</i> , "Activators and target genes of Rel/NF-kappaB transcription factors," <i>Oncogene</i> , 18:6853-6866, 1999.
	C23	Pan <i>et al.</i> , "Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages," <i>Biochem. Pharmacol.</i> , 60:1665-1676, 2000.
	C24	Plummer <i>et al.</i> , "Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex," <i>Oncogene</i> , 18:6013-6020, 1999.
	C25	Podar <i>et al.</i> , "Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells," <i>J. Biol. Chem.</i> , 278(8):5794-801, 2002.
✓	C26	Ramachandran <i>et al.</i> , "Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin," <i>Breast Cancer Res. and Treat.</i> , 54:269-278, 1999.

25527582.1

EXAMINER: *RL*DATE CONSIDERED: *8/11/05*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:234US	Serial No. 10/602,303
List of Patents and Publications for Applicant's		Applicant Bharat Aggarwal	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: June 24, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C27	Rao <i>et al.</i> , "Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound," <i>Cancer Res.</i> , 55:259-266, 1995.
	C28	Shishodia and Aggarwal, "Nuclear factor-B activation: a question of life and death," <i>J. Biochem Mol. Biol.</i> , 35:28-40, 2002.
	C29	Simon <i>et al.</i> , "Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships," <i>Cancer Lett.</i> , 129:111-116, 1998.
	C30	Singh and Aggarwal, "Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane)" <i>J. Biol. Chem.</i> , 270:24995-25000, 1995.
	C31	Singletary <i>et al.</i> , "Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin," <i>Cancer Lett.</i> , 103:137-141, 1996.
	C32	Sonneveld <i>et al.</i> , "Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914)," <i>Br. J. Haematol.</i> , 115(4):895-902.
	C33	Westerheide <i>et al.</i> , "The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition" <i>Mol. Cell. Biol.</i> 21:8428-8436, 2001.
	C34	Zhang <i>et al.</i> , "Zhongguo Yaolixue Tongbao, 17(6):702-704, 2001 (Abstract).
	C35	Zhang <i>et al.</i> , "Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells," <i>Carcinogenesis</i> , 20:445-451, 1999.
W	C36	Zhang <i>et al.</i> , "Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel," <i>Clin. Cancer Res.</i> , 5:343-353, 1999.

25527582.1

EXAMINER: <i>Alcock</i>	DATE CONSIDERED: 8/11/05
-------------------------	--------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.